Estimated Impact of Fungal Colonization in Cystic Fibrosis From Secondary Exploitation of MucoFong Database.
NCT ID: NCT03753828
Last Updated: 2019-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
57 participants
OBSERVATIONAL
2017-07-13
2018-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
NCT03736096
Epidemiology of Anaerobic Bacteria in Cystic Fibrosis Patients: Descriptive and Non-interventional Study
NCT04879381
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
NCT03312075
Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia
NCT05152875
Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients
NCT04735679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Relations between Aspergillus fumigatus or Candida albicans and lung function or clinical outcome of patients will be longitudinally analyzed taking as output variable FEV1, according to bibliography data available.
To assess the attributed fungal risk, the team will focus on the 57 patients de novo colonized by fungi at the second visit. Three physician experts will determine the impact of such fungal colonization on the patient clinical and respiratory parameters.
The expert conclusion concordance and statistical significance will be evaluated using the kappa score.
This project will be realized in collaboration with the groups of Prof. R. Thiebaut (Methodology and Epidemiology Service Bordeaux University Hospital, INSERM U1219 / INRIA SISTM) and Prof. M. Fayon (Department of Pediatrics, Pediatric reference centre) University Hospital of Bordeaux.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients de novo colonized by fungi
Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient whose diagnosis of cystic fibrosis has been validated on the criteria in force,
* Patient usually followed in one of the 7 centers involved in the PHRC,
* Patient aged at least 6 years without an upper age limit,
* Patient benefiting from a mycological assessment carried out in the context of the usual microbiological monitoring (good clinical practice),
* Cystic fibrosis Patient benefiting from a mycological assessment carried out in front of a clinical episode of aggravation requiring biological exploration,
* Patient who has signed informed consent at the time of inclusion,-patient affiliated with a social security scheme.
Exclusion Criteria
* Pulmonary transplant Patient,
* Patient or their parents (if the patient is a minor) refusing any participation in the study,
* Major incapable subject, under guardianship or under the protection of Justice,
* Refusal or inability to give informed consent.
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence DELHAES, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital University, Bordeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Bordeaux
Bourdeaux, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2017/34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.